Ovarian Cancer Diagnostics Market Report 2026

Ovarian Cancer Diagnostics Market Overview

• Ovarian Cancer Diagnostics market size has reached to $2.9 billion in 2025 • Expected to grow to $4.2 billion in 2030 at a compound annual growth rate (CAGR) of 7.7% • Growth Driver: Rising Prevalence Of Ovarian Cancer To Drive Market Growth • Market Trend: Immunogen And Takeda Collaborate To Advance Ovarian Cancer Treatment • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Ovarian Cancer Diagnostics Market?

Ovarian cancer diagnostics refers to the methods and procedures used to detect and diagnose ovarian cancer, including assessing symptoms, conducting physical examinations, and performing various diagnostic tests. Ovarian cancer is a malignant tumor that develops in the ovaries, which are part of the female reproductive system. The main types of ovarian cancer diagnostic products are instruments, kits, and reagents. Instruments are medical tools used to detect and diagnose ovarian cancer, including imaging devices (such as ultrasound and MRI), blood tests (CA-125, HE4), and tissue sampling techniques (biopsy, laparoscopy). The several types of diagnosis include biopsy, blood test, imaging, and others, which are used to diagnose distinct types of cancer, such as epithelial tumors, germ cell tumors, stromal cell tumors, and others. These are used by various end-users, including cancer diagnostic centers, hospital laboratories, and research institutes.

What Is The Ovarian Cancer Diagnostics Market Growth Forecast?

The ovarian cancer diagnostics market size is expected to see strong growth in the next few years. It will grow to $4.2 billion in 2030 at a compound annual growth rate (CAGR) of 7.7%. The growth in the forecast period can be attributed to increasing investments in precision oncology, rising demand for early-stage cancer detection, expansion of ai-driven diagnostic platforms, growing focus on personalized treatment planning, increasing research funding for women’s cancers. Major trends in the forecast period include increasing adoption of biomarker-based diagnostic tests, rising use of advanced imaging modalities, growing integration of ai in cancer detection, expansion of early screening programs, enhanced focus on personalized oncology diagnostics.

Global Ovarian Cancer Diagnostics Market Segmentation

1) By Product Type: Instruments, Kits, Reagents 2) By Diagnosis Type: Biopsy, Blood Test, Imaging, Other Diagnosis Types 3) By Cancer Type: Epithelial Tumor, Germ Cell Tumor, Stromal Cell Tumor 4) By End User: Cancer Diagnostic Centers, Hospital Laboratories Subsegments: 1) By Instruments: Imaging Systems, Biopsy Devices, Molecular Diagnostic Instruments 2) By Kits: Diagnostic Test Kits, Screening Kits 3) By Reagents: Antibodies, Enzymes, Assay Reagents

What Is The Driver Of The Ovarian Cancer Diagnostics Market?

The prevalence of gynecological cancer is expected to propel the growth of the ovarian cancer diagnosis market going forward. Gynecologic cancer refers to any cancer that begins in a woman's reproductive organs. Ovarian cancer diagnosis drugs help reduce the prevalence of gynecological cancer by treating and managing the disease, preventing recurrence, and improving patient outcomes by applying different therapies. For instance, in October 2025, according to Cancer Australia, an Australia-based government agency, in 2024, about 6,963 new cases of gynecological cancer were diagnosed in Australia. Therefore, the high prevalence of gynecological cancer is driving the growth of the ovarian cancer diagnosis market.

Key Players In The Global Ovarian Cancer Diagnostics Market

Major companies operating in the ovarian cancer diagnostics market are F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., AstraZeneca plc, Abbott Laboratories, GlaxoSmithKline plc, Eli Lilly and Company, GE HealthCare Technologies Inc., Quest Diagnostics Incorporated, Agilent Technologies Inc., Hologic Inc., Illumina Inc., PerkinElmer Inc., Sysmex Corporation, Bio-rad Laboratories Inc., Qiagen N.V., Natera Inc., Myriad Genetics Inc., Invitae Corporation, Guardant Health, Luminex Corporation, NanoString Technologies Inc., Siemens Healthcare Private Limited, Menarini Silicon Biosystems S.p.A., Precipio Inc., Angle plc

Global Ovarian Cancer Diagnostics Market Trends and Insights

Major companies operating in the ovarian cancer diagnostics market are forming partnerships to develop new products and strengthen their positions in the market. Partnerships and collaborations in the ovarian cancer diagnostics market enhance research, development, and commercialization efforts by leveraging the expertise, resources, and networks of multiple entities. For instance, in August 2023, ImmunoGen Inc., a US-based biotechnology company, partnered with Takeda Pharmaceutical Company Limited, a Japan-based pharmaceutical company, to develop and commercialize ELAHERE (mirvetuximab soravtansine-gynx) in Japan. ImmunoGen will receive upfront and milestone payments, along with double-digit royalties, while Takeda gains exclusive rights to develop and commercialize ELAHERE in Japan, reinforcing the commitment to bring this biomarker-directed ADC to patients with Folate Receptor Alpha (FRα)-Positive, Platinum-Resistant Ovarian Cancer in the Japanese market. The partnership helps to address an unmet need for individuals with platinum-resistant ovarian cancer and reinforces a shared commitment to advancing cancer treatment options globally.

What Are Latest Mergers And Acquisitions In The Ovarian Cancer Diagnostics Market?

In May 2025, Sonrai, a UK-based artificial intelligence and data analytics company, entered into a strategic partnership with AOA Dx to harness AI and multi-omics to revolutionize early ovarian cancer detection. This partnership aims to accelerate the development and clinical validation of AOA Dx’s serum-based multi-omic liquid biopsy test, improving early ovarian cancer diagnosis and patient outcomes. AOA Dx is a US-based biotechnology company focused on developing non-invasive diagnostic solutions for ovarian cancer.

Regional Outlook

North America was the largest region in the ovarian cancer diagnostics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain

What Defines the Ovarian Cancer Diagnostics Market?

The ovarian cancer diagnostic market includes revenues earned by entities by providing genetic testing, surgery, chemotherapy, target therapy, and hormone therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. The ovarian cancer diagnostic market also includes sales of ultrasound machines, biopsy tools, genetic testing kits, immunohistochemistry (IHC) kits, and ovarian cancer biomarker panels. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.